Home/Pipeline/LUNAR®-CF (ARCT-032)

LUNAR®-CF (ARCT-032)

Cystic Fibrosis

Phase 2Active, Recruiting

Key Facts

Indication

Cystic Fibrosis

Phase

Phase 2

Status

Active, Recruiting

Company

Arcturus Therapeutics

About Arcturus Therapeutics

Arcturus Therapeutics is a fully integrated, commercial-stage biotech focused on developing mRNA medicines for infectious diseases and rare genetic disorders. Its key achievement is the global approval of KOSTAIVE®, the world's first authorized self-amplifying mRNA COVID-19 vaccine, validating its proprietary technology platforms. The company's strategy is to leverage its LUNAR® delivery and STARR™ saRNA platforms to build a diversified pipeline, advance wholly-owned rare disease programs, and expand through strategic partnerships for vaccines and therapeutics.

View full company profile

Therapeutic Areas

Infectious Diseases Rare Genetic Disorders

Other Cystic Fibrosis Drugs

Drug	Company	Phase	Status
CB-280	Calithera Biosciences	Preclinical/Phase 1	Discontinued
Ensifentrine	Verona Pharma	Phase 2	Under MSD
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
Cystic fibrosis (CRISPR)	GeneToBe	Discovery	Active
Cystic fibrosis (undisclosed)	GeneToBe	Early Discovery	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
Targeted Lung Delivery	Nanite	Pre-clinical	Active
CFTR 100+ Panel	Agena Bioscience	Commercial	Active
RIG-301 CFTR	RIGImmune	Pre-clinical	Active
CBN-101	Carbon Biosciences	Preclinical	Active
RESP® Biosensor Evaluation (with Rutgers Health)	Strados Labs	Research Study	Active
KIT2014	Kither Biotech	Phase 2	Active